Literature DB >> 19836798

Conditional survival predictions after nephrectomy for renal cell carcinoma.

Pierre I Karakiewicz1, Nazareno Suardi, Umberto Capitanio, Hendrik Isbarn, Claudio Jeldres, Paul Perrotte, Maxine Sun, Vincenzo Ficarra, Richard Zigeuner, Jacques Tostain, Arnaud Mejean, Luca Cindolo, Allan J Pantuck, Arie S Belldegrun, Laurent Zini, Alexandre de la Taille, Denis Chautard, Jean-Luc Descotes, Shahrokh F Shariat, Antoine Valeri, Peter F A Mulders, Hervé Lang, Eric Lechevallier, Jean-Jacques Patard.   

Abstract

PURPOSE: Conditional survival implies that on average long-term cancer survivors have a better prognosis than do newly diagnosed individuals. We explored the effect of conditional survival in renal cell carcinoma.
MATERIALS AND METHODS: We studied 3,560 patients with renal cell carcinoma of all stages treated with nephrectomy. We applied conditional survival methodology to a previously reported posttreatment nomogram predicting survival after nephrectomy for patients with renal cell carcinoma stage I to IV. We used the same predictor variables that were integrated in the original multivariable Cox regression models, namely TNM stage, Fuhrman grade, tumor size and symptom classification. To validate the conditional survival nomogram we used an independent cohort of 3,560 patients from 15 institutions.
RESULTS: The 5-year survival of patients immediately after nephrectomy was 74.2%, which increased to 80.4%, 85.1%, 90.6% and 89.6% at 1, 2, 5 and 10 years after nephrectomy, respectively. The predicted probabilities varied by as much as 50% when, for example, predictions of renal cell carcinoma specific mortality at 10 years were made after nephrectomy vs 5 years later. Within the external validation cohort the accuracy of the conditional nomogram was 89.5%, 90.5%, 88.5% and 86.7% at 1, 2, 5 and 10 years after nephrectomy.
CONCLUSIONS: We developed (2,530) and externally validated (3,560) a conditional nomogram for predicting renal cell carcinoma specific mortality that allows consideration of the length of survivorship. Our tool provides the most realistic prognosis estimates with high accuracy.

Entities:  

Mesh:

Year:  2009        PMID: 19836798     DOI: 10.1016/j.juro.2009.08.084

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  11 in total

1.  Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma.

Authors:  Malte Rieken; Stephen A Boorjian; Luis A Kluth; Umberto Capitanio; Alberto Briganti; R Houston Thompson; Bradley C Leibovich; Laura-Maria Krabbe; Vitaly Margulis; Jay D Raman; Mikhail Regelman; Pierre I Karakiewicz; Morgan Rouprêt; Mohammad Abufaraj; Beat Foerster; Mithat Gönen; Shahrokh F Shariat
Journal:  World J Urol       Date:  2018-11-07       Impact factor: 4.226

2.  Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study.

Authors:  Lauren C Harshman; Wanling Xie; Georg A Bjarnason; Jennifer J Knox; Mary MacKenzie; Lori Wood; Sandy Srinivas; Ulka N Vaishampayan; Min-Han Tan; Sun-Young Rha; Frede Donskov; Neeraj Agarwal; Christian Kollmannsberger; Scott North; Brian I Rini; Daniel Y C Heng; Toni K Choueiri
Journal:  Lancet Oncol       Date:  2012-08-08       Impact factor: 41.316

3.  Conditional probability of survival nomogram for 1-, 2-, and 3-year survivors after an R0 resection for gastric cancer.

Authors:  Johan L Dikken; Raymond E Baser; Mithat Gonen; Michael W Kattan; Manish A Shah; Marcel Verheij; Cornelis J H van de Velde; Murray F Brennan; Daniel G Coit
Journal:  Ann Surg Oncol       Date:  2012-11-10       Impact factor: 5.344

4.  [Postoperative prognosis of chromophobic renal cell carcinoma: comparative analysis of the multinational CORONA database].

Authors:  M May; R Zigeuner; A Aziz; L Cindolo; C Gilfrich; L Schips; O De Cobelli; B Rocco; C De Nunzio; A Tubaro; I Coman; B Feciche; M Truss; B Hoschke; O Dalpiaz; A Stoltze; F Fenske; H-M Fritsche; T Chromecki; S Lebentrau; R S Figenshau; K Madison; M Sánchez-Chapado; M Del Carmen Santiago Martin; L Salzano; G Lotrecchiano; S Joniau; R Waidelich; C G Stief; S Brookman-May
Journal:  Urologe A       Date:  2014-02       Impact factor: 0.639

5.  Association of microvascular and capillary-lymphatic invasion with outcome in patients with renal cell carcinoma.

Authors:  Manuel S Eisenberg; John C Cheville; R Houston Thompson; Dharam Kaushik; Christine M Lohse; Stephen A Boorjian; Brian A Costello; Bradley C Leibovich
Journal:  J Urol       Date:  2013-01-23       Impact factor: 7.450

6.  Accuracy capabilities comparisons between Karakiewicz, Kattan and Cindolo nomograms in predicting outcomes for renal cancer carcinoma: A systematic review and meta-analysis.

Authors:  Giorgio Ivan Russo; Alessandro Di Rosa; Vincenzo Favilla; Eugenia Fragalà; Tommaso Castelli; Salvatore Privitera; Sebastiano Cimino; Giuseppe Morgia
Journal:  Can Urol Assoc J       Date:  2015 May-Jun       Impact factor: 1.862

7.  Renal cell carcinoma with rhabdoid-like features lack intracytoplasmic inclusion bodies and show aggressive behavior.

Authors:  Masaaki Sugimoto; Kenichi Kohashi; Kentaro Kuroiwa; Tatsuro Abe; Yuichi Yamada; Masaki Shiota; Kenjiro Imada; Seiji Naito; Yoshinao Oda
Journal:  Virchows Arch       Date:  2015-12-09       Impact factor: 4.064

8.  Prognostic significance of early recurrence: a conditional survival analysis in patients with resected colorectal liver metastasis.

Authors:  Marcus C B Tan; Jean M Butte; Mithat Gonen; Nancy Kemeny; Yuman Fong; Peter J Allen; T Peter Kingham; Ronald P Dematteo; William R Jarnagin; Michael I D'Angelica
Journal:  HPB (Oxford)       Date:  2013-06-19       Impact factor: 3.647

9.  Conditional survival in patients with gallbladder cancer.

Authors:  Yi-Jun Kim; Kyubo Kim
Journal:  Chin J Cancer       Date:  2017-10-30

10.  C-reactive protein in patients with advanced metastatic renal cell carcinoma: usefulness in identifying patients most likely to benefit from initial nephrectomy.

Authors:  Hiroki Ito; Koichi Shioi; Takayuki Murakami; Akitoshi Takizawa; Futoshi Sano; Takashi Kawahara; Nobuhiko Mizuno; Kazuhide Makiyama; Noboru Nakaigawa; Takeshi Kishida; Takeshi Miura; Yoshinobu Kubota; Masahiro Yao
Journal:  BMC Cancer       Date:  2012-08-02       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.